share_log

開拓藥業(09939.HK)首創外用藥物福瑞他恩II期臨床試驗達主要終點

The first external product of 09939.HK, Freitaen, has reached the main points in the II trial.

AASTOCKS ·  Dec 2, 2022 03:25

$KINTOR PHARMA-B (09939.HK)$It has been announced that China's II trial trial has reached a major point in the treatment of adult female androgen disorder "AGA" by Freitaan, a product independently developed and the first of its kind, "KX-826".

Freitain is an androgen receptor antagonist used to treat AGA and acne in the same category.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment